Excellent Outcomes Using a Non-Myeloablative Conditioning with Thiotepa and Post -Transplant Cyclophosphamide in Adults Undergoing a Matched Related Donor Bone Marrow Transplant for Severe Sickle Cell Disease

Allogeneic hematopoietic stem-cell transplantation (HSCT) is a validated curative therapy for sickle cell disease (SCD). The excellent outcomes of matched related donor (MRD) HSCT over the last 3 decades confirm the role of HLA-identical sibling BMT for SCD (PMID: 27965196). However, event-free surv...

Full description

Saved in:
Bibliographic Details
Published in:Transplantation and cellular therapy 2024-02, Vol.30 (2), p.S55-S56
Main Authors: Alasbali, Reem, Alzahrani, Mohsen, Alhayli, Saud, Rasheed, Walid K., Wilkerson, Karina, Fakih, Riad El, AlAhmari, Bader, Samarkandi, Hadeel, Albabtain, Abdulwahab, Alotaibi, Ahmad, Ahmed, Syed O, Saad, Ayman, Alzahrani, Hazzaa, Almohareb, Fahad, Aljurf, Mahmoud, Kassim, Adetola A., AlAhmari, Ali
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allogeneic hematopoietic stem-cell transplantation (HSCT) is a validated curative therapy for sickle cell disease (SCD). The excellent outcomes of matched related donor (MRD) HSCT over the last 3 decades confirm the role of HLA-identical sibling BMT for SCD (PMID: 27965196). However, event-free survival (EFS) was lower with increasing age at transplantation (P
ISSN:2666-6367
2666-6367
DOI:10.1016/j.jtct.2023.12.090